Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiovascular Magnetic Resonance
Published in: Journal of Cardiovascular Magnetic Resonance 1/2012

Open Access 01-12-2012 | Review

Cardiovascular magnetic resonance in systemic hypertension

Authors: Alicia M Maceira, Raad H Mohiaddin

Published in: Journal of Cardiovascular Magnetic Resonance | Issue 1/2012

Login to get access

Abstract

Systemic hypertension is a highly prevalent potentially modifiable cardiovascular risk factor. Imaging plays an important role in the diagnosis of underlying causes for hypertension, in assessing cardiovascular complications of hypertension, and in understanding the pathophysiology of the disease process. Cardiovascular magnetic resonance (CMR) provides accurate and reproducible measures of ventricular volumes, mass, function and haemodynamics as well as uniquely allowing tissue characterization of diffuse and focal fibrosis. In addition, CMR is well suited for exclusion of common secondary causes for hypertension. We review the current and emerging clinical and research applications of CMR in hypertension.
Appendix
Available only for authorised users
Literature
1.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet. 2005, 365: 217-223.PubMed
2.
Levy D, Garrison R, Savage D, Kannel W, Castelli W: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990, 322: 1561-1566. 10.1056/NEJM199005313222203.PubMed
3.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002, 360: 1903-1913.PubMed
4.
Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C: Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003, 41: 218-223. 10.1161/01.HYP.0000052830.02773.E4.PubMed
5.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003, 42: 1206-1252. 10.1161/01.HYP.0000107251.49515.c2.PubMed
6.
The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): Guidelines for the management of arterial Hipertensión. European Heart Journal. 2007, 28: 1462-1536.
7.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension. 2009, 27: 2121-2158. 10.1097/HJH.0b013e328333146d.PubMed
8.
American College of Cardiology Foundation Task Force on Expert Consensus Documents, Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK: ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010, 55: 2614-2662. 10.1016/j.jacc.2009.11.011.
9.
Ghali J, Liao Y, Simmons B, Castaner A, Cao G, Cooper R: The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 1992, 117: 831-836.PubMed
10.
Kaplinsky E: Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther. 1994, 8: 549-556. 10.1007/BF00877223.PubMed
11.
Charoenpanichkit C, Morgan TM, Hamilton CA, Wallace EL, Robinson K, Ntim WO, Hundley WG: Left ventricular hypertrophy influences cardiac prognosis in patients undergoing dobutamine cardiac stress testing. Circ Cardiovasc Imaging. 2010, 3: 392-397. 10.1161/CIRCIMAGING.109.912071.PubMedCentralPubMed
12.
Sokolow M, Lyon TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949, 37: 161-186. 10.1016/0002-8703(49)90562-1.PubMed
13.
Romhilt D, Estes EJ: A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J. 1968, 75: 752-758. 10.1016/0002-8703(68)90035-5.PubMed
14.
Woythaler J, Singer S, Kwan O, Meltzer R, Reubner B, Bommer W, DeMaria A: Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: comparison with postmortem mass measurements. J Am Coll Cardiol. 1983, 2: 305-311. 10.1016/S0735-1097(83)80167-3.PubMed
15.
Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M: New gender-specific partition values for ECG criteria of left ventricular hypertrophy: recalibration against cardiac MRI. Hypertension. 2004, 44: 175-179. 10.1161/01.HYP.0000135249.66192.30.PubMed
16.
Germain P, Roul G, Kastler B, Mossard J, Bareiss P, Sacrez A: Inter-study variability in left ventricular mass measurement: comparison between M-mode echocardiography and MRI. Eur Heart J. 1992, 13: 1011-1019.PubMed
17.
Myerson SG, Montgomery HE, World MJ, Pennell DJ: Left ventricular mass: reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension. 2002, 40: 673-678. 10.1161/01.HYP.0000036401.99908.DB.PubMed
18.
Kuhl H, Bucker A, Franke A, Maul S, Nolte-Ernsting C, Reineke T, Hoffmann R, Günther RW, Hanrath P: Transesophageal 3-dimensional echocardiography: in vivo determination of left ventricular mass in comparison with magnetic resonance imaging. J Am Soc Echocardiogr. 2000, 13: 205-215.PubMed
19.
Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ: Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol. 2002, 90: 29-34. 10.1016/S0002-9149(02)02381-0.PubMed
20.
Maceira AM, Prasad SK, Khan M, Pennell DJ: Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006, 8: 417-426. 10.1080/10976640600572889.PubMed
21.
Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ: Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000, 2: 271-278. 10.3109/10976640009148691.PubMed
22.
Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, Claessens T, Gillebert TC, St John-Sutton M, Rietzschel ER: Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension. 2010, 56: 91-98. 10.1161/HYPERTENSIONAHA.110.150250.PubMedCentralPubMed
23.
Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E: Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009, 54: 220-228. 10.1016/j.jacc.2009.05.006.PubMed
24.
Khouri MG, Peshock RM, Ayers CR, De Lemos JA, Drazner MH: A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Circ Cardiovasc Imaging. 2010, 3: 164-171. 10.1161/CIRCIMAGING.109.883652.PubMed
25.
Fox ER, Taylor J, Taylor H, Han H, Samdarshi T, Arnett D, Myerson M: Left ventricular geometric patterns in the Jackson cohort of the Atherosclerotic Risk in Communities (ARIC) Study: clinical correlates and influences on systolic and diastolic dysfunction. Am Heart J. 2007, 153: 238-244. 10.1016/j.ahj.2006.09.013.PubMed
26.
Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, Poisa P, Rizzoni D, Castellano M, Agabiti-Rosei E: Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2004, 43: 731-738. 10.1161/01.HYP.0000121223.44837.de.PubMed
27.
Rodriguez CJ, Diez-Roux AV, Moran A, Jin Z, Kronmal RA, Lima J, Homma S, Bluemke DA, Barr RG: Left ventricular mass and ventricular remodeling among Hispanic subgroups compared with non-Hispanic blacks and whites: MESA (Multi-ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010, 55: 234-242. 10.1016/j.jacc.2009.08.046.PubMedCentralPubMed
28.
De Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laraqh JH: Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation. 1996, 93: 259-265.PubMed
29.
Ugander M, Carlsson M, Arheden H: Short-axis epicardial volume change is a measure of cardiac left ventricular short-axis function, which is independent of myocardial wall thickness. Am J Physiol Heart Circ Physiol. 2010, 298: H530-H535. 10.1152/ajpheart.00153.2009.PubMed
30.
Jung B, Schneider B, Markl M, Saurbier B, Geibel A, Hennig J: Measurement of left ventricular velocities: phase contrast MRI velocity mapping versus tissue-doppler-ultrasound in healthy volunteers. J Cardiovasc Magn Reson. 2004, 6: 777-783. 10.1081/JCMR-200036116.PubMed
31.
Sironi AM, Pingitore A, Ghione S, De Marchi D, Scattini B, Positano V, Muscelli E, Ciociaro D, Lombardi M, Ferrannini E, Gastaldelli A: Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension. 2008, 51: 282-288. 10.1161/HYPERTENSIONAHA.107.098640.PubMed
32.
Biedeman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell’Italia LJ: Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008, 52: 279-286. 10.1161/HYPERTENSIONAHA.108.109819.
33.
Pennell DJ, Sechtem U, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ: Clinical indications for cardiovascular magnetic resonance (CMR): Consensus panel report. Eur Heart J. 2004, 25: 1940-1965. 10.1016/j.ehj.2004.06.040.PubMed
34.
Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, Devereux R, Ibsen H: Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am Heart J. 2002, 144: 530-537. 10.1067/mhj.2002.124863.PubMed
35.
Friedrich MG, Dahlof B, Sechtem U, Unger T, Knecht M, Dietz R: TELMAR Investigators. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension–a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. J Renin Angiotensin Aldosterone Syst. 2003, 4: 234-243. 10.3317/jraas.2003.038.PubMed
36.
Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause J, Krause S, Burns D, Williams GH: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003, 108: 1831-1838. 10.1161/01.CIR.0000091405.00772.6E.PubMed
37.
Reichek N, Devereux RB, Rocha RA, Hilkert R, Hall D, Purkayastha D, Pitt B: Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. Hypertension. 2009, 54: 731-737. 10.1161/HYPERTENSIONAHA.109.130641.PubMed
38.
Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B: Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009, 119: 530-537. 10.1161/CIRCULATIONAHA.108.826214.PubMed
39.
Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ: Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005, 111: 186-193. 10.1161/01.CIR.0000152819.97857.9D.PubMed
40.
Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz Z, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U: Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008, 51: 1022-1030. 10.1016/j.jacc.2007.10.049.PubMed
41.
Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, Paetsch I: Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol. 2010, 106: 1016-1022. 10.1016/j.amjcard.2010.05.036.PubMed
42.
Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD, Ostman-Smith I, Casadei B, Watkins H, Neubauer S: Differentiation of athlete’s heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2005, 7: 551-558. 10.1081/JCMR-200060631.PubMed
43.
Díez J, López B, González A, Querejeta R: Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol. 2001, 16: 328-335. 10.1097/00001573-200111000-00003.PubMed
44.
Rudolph A, Abdel-Aty H, Bohl S, Boyé P, Zagrosek A, Dietz R, Schulz-Menger J: Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol. 2009, 53: 284-291. 10.1016/j.jacc.2008.08.064.PubMed
45.
Mewton M, Liu CY, Croisille P, Bluemke D, Lima J: Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011, 57: 891-903. 10.1016/j.jacc.2010.11.013.PubMed
46.
Díez M: Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens. 2007, 9: 546-550. 10.1111/j.1524-6175.2007.06626.x.
47.
Querejeta R, Varo N, López B, Larman M, Artiñano E, Etayo JC, Martínez Ubago JL, Gutiérrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindán JP, Díez J: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000, 101: 1729-1735.PubMed
48.
Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlof B, Nicholls MG, Smith RD, Gilles L, Magrini F, Zanchetti A: Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004, 110: 552-557. 10.1161/01.CIR.0000137118.47943.5C.PubMed
49.
Garcia MJ, Firstenberg MS, Greenberg NL, Smedira N, Rodriguez L, Prior D, Thomas JD: Estimation of left ventricular operating stiffness from Doppler early filling deceleration time in humans. Am J Physiol Heart Circ Physiol. 2001, 280: H554-H561.PubMed
50.
Maceira AM, Barba J, Varo N, Beloqui O, Díez J: Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension. 2002, 39: 923-928. 10.1161/01.HYP.0000014616.48920.8F.PubMed
51.
Maceira AM, Barba J, Beloqui O, Díez J: Ultrasonic backscatter and diastolic function in hypertensive patients. Hypertension. 2002, 40: 239-243. 10.1161/01.HYP.0000030154.90042.4C.PubMed
52.
Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM: The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000, 343: 1445-1453. 10.1056/NEJM200011163432003.PubMed
53.
Moon JCC, Reed E, Sheppard MN, Elkington AG, SiewYen H, Burke M, Petro M, Pennell DJ: The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004, 43: 2260-2264. 10.1016/j.jacc.2004.03.035.PubMed
54.
Krittayaphong R, Boonyasirinant T, Chaithiraphan V, Maneesai A, Saiviroonporn P, Nakyen S, Thanapiboonpol P, Yindeengam A, Udompanturak S: Prognostic value of late gadolinium enhancement in hypertensive patients with known or suspected coronary artery disease. Int J Cardiovasc Imaging. 2010, 26 (Suppl 1): 123-131.PubMed
55.
Andersen K, Hennersdorf M, Cohnen M, Blondin D, Mödder U, Poll LW: Myocardial delayed contrast enhancement in patients with arterial hypertension: initial results of cardiac MRI. Eur J Radiol. 2009, 71: 75-81. 10.1016/j.ejrad.2008.03.009.PubMed
56.
Flacke SJ, Fischer SE, Lorenz CH: Measurement of gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic myocardial infarction. Radiology. 2001, 218: 703-710.PubMed
57.
Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE: Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopatic or dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008, 295: H1234-H1242. 10.1152/ajpheart.00429.2008.PubMedCentralPubMed
58.
Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M: Dysfunction in congenital heart disease. Circ Cardiovasc Imaging. 2010, 3: 727-734. 10.1161/CIRCIMAGING.108.842096.PubMedCentralPubMed
59.
Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, Sivananthan MU: Myocardial T1 mapping, application to patients with acute and chronic myocardial infarction. Magn Reson Med. 2007, 58: 34-40. 10.1002/mrm.21272.PubMed
60.
Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, Sibley CT, Chen MY, Bandettini WP, Arai AE: Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012, 10.1093/eurheartj/ehr481. [Epub ahead of print]
61.
Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, Sibley CT, Kellman P, Arai AE, Bluemke DA: Myocardial T1 and Extracellular Volume Fraction Mapping at 3 Tesla. J Cardiovasc Magn Reson. 2011, 13: 75-10.1186/1532-429X-13-75.PubMedCentralPubMed
62.
Piechnik SK, Ferreira VM, Dall’Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD: Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1- mapping at 1.5 and 3 T within a 9 heartbeat breathhold. Journal of Cardiovascular Magnetic Resonance. 2010, 12: 69-80. 10.1186/1532-429X-12-69.PubMedCentralPubMed
63.
White SK, Piechnik SK, Neubauer S, Robson MD, Moon J: Histological validation of ShMOLLI equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis. Journal of Cardiovascular Magnetic Resonance. 2012, 14 (Suppl 1): O111-10.1186/1532-429X-14-S1-O111.PubMedCentral
64.
Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL: Systolic and diastolic heart failure in the community. JAMA. 2006, 296: 2209-2216. 10.1001/jama.296.18.2209.PubMed
65.
Kawaji K, Codella NC, Prince MR, Chu CW, Shakoor A, LaBounty TM, Min JK, Swaminathan RV, Devereux RB, Wang Y, Weinsaft JW: Automated segmentation of routine clinical cardiac magnetic resonance imaging for assessment of left ventricular diastolic dysfunction. Circ Cardiovasc Imaging. 2009, 2: 476-484. 10.1161/CIRCIMAGING.109.879304.PubMed
66.
Rossi A, Temporelli PL, Quintana M, Dini FL, Ghio S, Hillis GS, Klein AL, Marsan NA, Prior DL, Yu CM, Poppe KK, Doughty RN, Whalley GA: MeRGE Heart Failure Collaborators. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure). Eur J Heart Fail. 2009, 11: 929-936. 10.1093/eurjhf/hfp112.PubMed
67.
Bangalore S, Yao SS, Chaudhry FA: Role of left atrial size in risk stratification and prognosis of patients undergoing stress echocardiography. J Am Coll Cardiol. 2007, 50: 1254-1262. 10.1016/j.jacc.2007.06.025.PubMed
68.
Therkelsen SK, Groenning BA, Svendsen JH, Jensen GB: Atrial and ventricular volume and function in persistent and permanent atrial fibrillation, a magnetic resonance imaging study. J Cardiovasc Magn Reson. 2005, 7: 465-473. 10.1081/JCMR-200053618.PubMed
69.
Maceira A, Cosín-Sales J, Roughton M, Prasad SK, Pennell DJ: Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010, 12: 65-72. 10.1186/1532-429X-12-65.PubMedCentralPubMed
70.
Sytkowski PA, Kannel WB, D’Agostino RB: Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med. 1990, 322: 1635-1641. 10.1056/NEJM199006073222304.PubMed
71.
Terry PD, Abramson JL, Neaton JD: MRFIT Research Group. Blood pressure and risk of death from external causes among men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol. 2007, 165: 294-301.PubMed
72.
Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, Alexander RW: Hypertension and left ventricular hypertrophy are associated with impaired endothelium mediated relaxation in human coronary resistance vessels. Circulation. 1993, 87: 86-93.PubMed
73.
Bernhardt P, Levenson B, Albrecht A, Engels T, Strohm O: Detection of cardiac small vessel disease by adenosine-stress magnetic resonance. Int J Cardiol. 2007, 121: 261-266. 10.1016/j.ijcard.2006.11.008.PubMed
74.
Vogel-Claussen J, Skrok J, Dombroski D, Shea SM, Shapiro EP, Bohlman M, Lorenz CH, Lima JA, Bluemke DA: Comprehensive adenosine stress perfusion MRI defines the etiology of chest pain in the emergency room: Comparison with nuclear stress test. J Magn Reson Imaging. 2009, 30: 753-762. 10.1002/jmri.21899.PubMedCentralPubMed
75.
Yilmaz A, Athanasiadis A, Mahrholdt H, Voehringer M, Ong P, Hill S, Kispert EM, Seebo M, Sechtem U: Diagnostic value of perfusion cardiovascular magnetic resonance in patients with angina pectoris but normal coronary angiograms assessed by intracoronary acetylcholine testing. Heart. 2010, 96: 372-379. 10.1136/hrt.2009.174367.PubMed
76.
Nitenberg A, Pham I, Antony I, Valensi P, Attali JR, Chemla D: Cardiovascular outcome of patients with abnormal coronary vasomotion and normal coronary arteriography is worse in type 2 diabetes mellitus than in arterial hypertension: a 10 year follow-up study. Atherosclerosis. 2005, 183: 113-120. 10.1016/j.atherosclerosis.2005.02.030.PubMed
77.
Schwitter J, Wacker C, van Rossum A, Lombardi M, Al-Saadi N, Ahlstrom H, Dill T, Larsson HB, Flamm S, Marquardt M, Johansson L: MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008, 29: 480-489. 10.1093/eurheartj/ehm617.PubMed
78.
Schwitter J, Nanz D, Kneifel S, Bertschinger K, Buchi M, Knusel PR, Marincek B, Luscher TF, von Schulthess GK: Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation. 2001, 103: 2230-2235.PubMed
79.
Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, Ball SG, Plein S: Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012, 379: 453-460. 10.1016/S0140-6736(11)61335-4.PubMedCentralPubMed
80.
Plein S, Greenwood JP, Ridgway JP, Cranny G, Ball SG, Sivananthan MU: Assessment of non-ST-segment elevation acute coronary syndromes with cardiac magnetic resonance imaging. J Am Coll Cardiol. 2004, 44: 2173-2181. 10.1016/j.jacc.2004.08.056.PubMed
81.
Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM: Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999, 100: 1992-2002.PubMed
82.
Malayeri AA, Natori S, Bahrami H, Bertoni AG, Kronmal R, Lima JA, Bluemke DA: Relation of aortic wall thickness and distensibility to cardiovascular risk factors (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2008, 102: 491-496. 10.1016/j.amjcard.2008.04.010.PubMedCentralPubMed
83.
Redheuil A, Yu WC, Wu CO, Mousseaux E, de Cesare A, Yan R, Kachenoura N, Bluemke D, Lima JA: Reduced ascending aortic strain and distensibility: earliest manifestations of vascular aging in humans. Hypertension. 2010, 55: 319-326. 10.1161/HYPERTENSIONAHA.109.141275.PubMedCentralPubMed
84.
Gupta S, Berry JD, Ayers CR, Peshock RM, Khera A, de Lemos JA, Patel PC, Markham DW, Drazner MH: Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease:the Dallas Heart Study. JACC Cardiovasc Imaging. 2010, 3: 605-613. 10.1016/j.jcmg.2010.03.005.PubMed
85.
Mani V, Muntner P, Gidding SS, Aguiar SH, El Aidi H, Weinshelbaum KB, Taniguchi H, van der Geest R, Reiber JH, Bansilal S, Farkouh M, Fuster V, Postley JE, Woodward M, Fayad ZA: Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events. J Cardiovasc Magn Reson. 2009, 11: 10-10.1186/1532-429X-11-10.PubMedCentralPubMed
86.
Santos RD, Nasir K: Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis?. Atherosclerosis. 2009, 205: 349-356. 10.1016/j.atherosclerosis.2008.12.017.PubMed
87.
Cappendijk VC, Cleutjens KB, Kessels AG, Heeneman S, Schurink GW, Welten RJ, Mess WH, Daemen MJ, van Engelshoven JM, Kooi ME: Assessment of human atherosclerotic carotid plaque components with multisequence MR imaging: initial experience. Radiology. 2005, 234: 487-492. 10.1148/radiol.2342032101.PubMed
88.
Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ: Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002, 106: 2884-2887. 10.1161/01.CIR.0000041255.88750.F0.PubMed
89.
Mohiaddin RH, Burman ED, Prasad SK, Varghese A, Tan RS, Collins SA, Hughes RL, Gatejouse PD, Jhooti P, Longmore DB, Yang GZ, Firmin DN, Pennell DJ: Glagov remodeling of the atherosclerotic aorta demonstrated by cardiovascular magnetic resonance: the CORDA asymptomatic subject plaque assessment research (CASPAR) project. J Cardiovasc Magn Reson. 2004, 6: 517-525. 10.1081/JCMR-120030576.PubMed
90.
Morishige K, Kacher DF, Libby P, Josephson L, Ganz P, Weissleder R, Aikawa M: High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation. 2010, 122: 1707-1715. 10.1161/CIRCULATIONAHA.109.891804.PubMedCentralPubMed
91.
Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C: Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation. 2002, 106: 1368-1373. 10.1161/01.CIR.0000028591.44554.F9.PubMed
92.
Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL: Magnetic resonance images lipid, fibrous, calcified, hemorrhagic and thrombotic components of human atherosclerosis in vivo. Circulation. 1996, 94: 932-938.PubMed
93.
Frydrychowicz A, Stalder AF, Russe MF, Bock J, Bauer S, Harloff A, Berger A, Langer M, Hennig J, Markl M: Three-dimensional analysis of segmental wall shear stress in the aorta by flow-sensitive four-dimensional-MRI. J Magn Reson Imaging. 2009, 30: 77-84. 10.1002/jmri.21790.PubMed
94.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002, 288: 2981-2997. 10.1001/jama.288.23.2981.
95.
Crowley JJ, Santos RM, Peter RH, Puma JA, Schwab SJ, Phillips HR, Stack RS, Conlon PJ: Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J. 1998, 136: 913-918. 10.1016/S0002-8703(98)70138-3.PubMed
96.
Safian RD, Textor SC: Renal-artery stenosis. N Engl J Med. 2001, 344: 431-442. 10.1056/NEJM200102083440607.PubMed
97.
Conlon PJ, Little MA, Pieper K, Mark DB: Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001, 60: 1490-1497. 10.1046/j.1523-1755.2001.00953.x.PubMed
98.
The ASTRAL Investigators: Revascularization versus Medical Therapy for Renal-Artery Stenosis. N Engl J Med. 2009, 361: 1953-1962.
99.
Bakker J, Beek FJ, Beutler JJ, Hene RJ, de Kort GA, de Lange EE, Moons KG, Mali WP: Renal artery stenosis and accessory renal arteries: accuracy of detection and visualization with gadolinium-enhanced breath-hold MR angiography. Radiology. 1998, 207: 497-504.PubMed
100.
Vasbinder GB, Nelemans PJ, Kessels AG, Kroon AA, de Leeuw PW, van Engelshoven JM: Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med. 2001, 135: 401-411.PubMed
101.
Tan KT, van Beek EJ, Brown PW, van Delden OM, Tijssen J, Ramsay LE: Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. Clin Radiol. 2002, 57: 617-624. 10.1053/crad.2002.0941.PubMed
102.
Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett Al, Garrett RW, Djamali A: Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007, 243: 148-157. 10.1148/radiol.2431062144.PubMed
103.
Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002, 40: 892-896. 10.1161/01.HYP.0000040261.30455.B6.PubMed
104.
Sohaib SA, Peppercorn PD, Allan C, Monson JP, Grossman AB, Besser GM, Reznek RH: Primary hyperaldosteronism (Conn Syndrome): MR imaging findings. Radiology. 2000, 214: 527-531.PubMed
105.
Nussberger J: Investigating mineralocorticoid hypertension. J Hypertens. 2003, 21 (Suppl 2): S25-S30.
106.
Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, Rosei EA, Mantero F, Fallo F: Left ventricular structural and functional characteristics in Cushing’s syndrome. J Am Coll Cardiol. 2003, 41: 2275-2279. 10.1016/S0735-1097(03)00493-5.PubMed
107.
Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI: Hypertension in patients with Cushing’s disease: pathophysiology, diagnosis, and management. Curr Hypertens Rep. 2005, 7: 212-218. 10.1007/s11906-005-0013-4.PubMed
108.
Mitchell DG, Crovello M, Matteucci T, Peterson RO, Miettinen MM: Beningn adrenocortical masses: diagnosis with chemical shift MR imaging. Radiology. 1992, 185: 345-351.PubMed
109.
Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T: Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004, 27: 193-202. 10.1291/hypres.27.193.PubMed
110.
Zelinka T, Strauch B, Petrák O, Holaj R, Vranková A, Weisserová H, Pacák K, Widimský J: Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens. 2005, 23: 2033-2039. 10.1097/01.hjh.0000185714.60788.52.PubMed
111.
Katira R, Rathore VS, Lip GY, Singh SP: Coarctation of aorta. J Hum Hypertens. 1997, 11: 537-538. 10.1038/sj.jhh.1000477.PubMed
112.
Hager A, Kanz S, Kaemmerer H, Schreiber C, Hess J: Coarctation Long-term Assessment (COALA): Significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of restenosis and prosthetic material. J Thorac Cardiovasc Surg. 2007, 134: 738-745. 10.1016/j.jtcvs.2007.04.027.PubMed
113.
Alpert BS, Bain HH, Balfe JW, Kidd BS, Olley PM: Role of the renin-angiotensin-aldosterone system in hypertensive children with coarctation of the aorta. Am J Cardiol. 1979, 43: 828-834. 10.1016/0002-9149(79)90085-7.PubMed
114.
Johnson D, Perrault H, Vobecky SJ, Trudeau F, Dalvin E, Fournier A: Resetting of the cardiopulmonary baroreflex 10 years after surgical repair of coarctation of the aorta. Heart. 2001, 85: e318-e325. 10.1136/heart.85.3.318.
115.
Miller-Hance WC, Silverman NH: Transesophageal echocardiography (TEE) in congenital heart disease with focus on the adult. Cardiol Clin. 2000, 18: 861-892. 10.1016/S0733-8651(05)70185-5.PubMed
116.
Cademartiri F, Nieman K, Raaijmakers RH, Alfieri O, Krestin GP: Three-dimensional volume rendering with multislice computed tomography in the evaluation of aortic coarctation. Ital Heart J. 2003, 4: 286-287.PubMed
117.
Mendelsohn AM, Banerjee A, Donnelly LF, Schwartz DC: Is echocardiography or magnetic resonance imaging superior for precoarctation angioplasty evaluation?. Cathet Cardiovasc Diagn. 1997, 42: 26-30. 10.1002/(SICI)1097-0304(199709)42:1<26::AID-CCD7>3.0.CO;2-B.PubMed
118.
Puranik R, Tsang VT, Puranik S, Jones R, Cullen S, Bonhoeffer P, Hughes ML, Taylor AM: Late magnetic resonance surveillance of repaired coarctation of the aorta. Eur J Cardiothorac Surg. 2009, 36: 91-95. 10.1016/j.ejcts.2009.02.056.PubMedCentralPubMed
Metadata
Title
Cardiovascular magnetic resonance in systemic hypertension
Authors
Alicia M Maceira
Raad H Mohiaddin
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Cardiovascular Magnetic Resonance / Issue 1/2012
Electronic ISSN: 1532-429X
DOI
https://doi.org/10.1186/1532-429X-14-28

Other articles of this Issue 1/2012

Journal of Cardiovascular Magnetic Resonance 1/2012 Go to the issue

Research

Undersampled Cine 3D tagging for rapid assessment of cardiac motion

Research

MRI active guidewire with an embedded temperature probe and providing a distinct tip signal to enhance clinical safety

Technical notes

A multi-center inter-manufacturer study of the temporal stability of phase-contrast velocity mapping background offset errors

Research

Towards real-time cardiovascular magnetic resonance guided transarterial CoreValve implantation: in vivo evaluation in swine

Research

Thrombus aspiration during primary percutaneous coronary intervention is associated with reduced myocardial edema, hemorrhage, microvascular obstruction and left ventricular remodeling

Research

Quantitative myocardial perfusion in mice based on the signal intensity of flow sensitized CMR